Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91

Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause (2010) 1.56

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat (2008) 1.56

Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer (2004) 0.97

Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis (2013) 0.94

Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls. Breast Cancer Res Treat (2012) 0.93

Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw (2010) 0.81

Not all depression is created equal: sex interacts with disease to precipitate depression. Biol Sex Differ (2013) 0.77

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol (2015) 0.75

Choices for young women at intermediate risk of breast cancer. Curr Oncol (2012) 0.75

Nanotamoxifen Delivery System: Toxicity Assessment After Oral Administration and Biodistribution Study After Intravenous Delivery of Radiolabeled Nanotamoxifen. World J Nucl Med (2016) 0.75

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prev Res (Phila) (2015) 0.75